|
Hatteras Venture Partners III (HVP III) is an $83 million venture capital fund focused on seed and early stage investments in biopharmaceuticals, medical devices, diagnostics, and related areas of human medicine. Launched in January of 2007, HVP III can invest in any companies in the United States but has an emphasis on opportunities in the southeastern US.
ArtusLabs
ArtusLabs is a technology company that enables scientific data management and workplace collaboration for research-driven entities such as biotech companies, pharmaceutical companies, and academic institutes and laboratories. Blending together the management of unstructured information and insights with social networking, personal publication, and refined data mining, ArtusLabs can significantly enhance internal and external research communication and research management. The company's "Genius" product line provides significant innovation for selecting optimal purifications, formulations, reactions, and other activities.
CancerGuide provides diagnostic tests that enable individualized cancer treatment decisions. The diagnostic tests will aid clinicians in determining the risk of cancer recurrence as well as selecting the most appropriate therapeutic course for patients. The company will have three clinical diagnostics products, CancerGuideRx for clinical decision support and CancerGuideLP and CancerGuideCP for lung and colon cancer prognosis. Additionally, CancerGuide will provide diagnostic development services to pharmaceutical and biotechnology companies with the potential to reposition second-line treatment as first-line in chemo-resistant populations, to identify sub-populations of patients that respond more effectively to treatment, and to aid in the early discovery of pathways that may be a potential target for new drugs.
Clinipace is a digital clinical research organization (dCRO), providing technology-driven clinical services for phase I-IV clinical trials and registries, serving biopharmaceutical and medical device companies as well as academic medical centers. Clinipace is built on TEMPO™, an integrated EDC and Study Management platform integrating the core functional needs of clinical studies or grant management programs - Clinical Data Capture, Study Management, and Grant Tracking into a single, highly scalable, easy to use platform.
Embrella Cardiovascular, Inc., is developing an embolic protection device called the Embrella Embolic Deflector™. A large growth market exists related to percutaneous aortic valve replacement (PAVR), a relatively new procedure that involves non-surgical, catheter-based implantation of a replacement aortic valve for the treatment of aortic stenosis. During the PAVR procedure, a major complication is the increased incidence of stroke from debris dislodging from the diseased aortic valve. The Embrella device acts as a filter/deflector for these potential emboli by positioning it at the origin of the carotid arteries.
Histosonics is a medical device company that has developed a system for treating BPH through histotripsy, a non-invasive, image guided, robotically controlled system for precise tissue ablation. In addition to BPH treatment and prostate cancer ablation, histotripsy is applicable to many other diseases including non-invasive solid tumor ablation and thrombolysis for deep vein thrombosis.
Pathfinder is a medical device company dedicated to increasing the number and effectiveness of surgeries on abdominal and other soft tissue organs. Pathfinder is the first company to receive FDA clearance for a medical device to navigate liver surgery using preoperative medical images. Pathfinder's products, Explorer and Scout, improve surgical precision by allowing surgeons to "see through" the organ they are operating on by registering the surgical instrument in three-dimensional space onto pre-operative patient medical images. These products will eventually allow surgeons to perform minimally invasive abdominal procedures.
PhaseBio is a biopharmaceutical company applying a flexible new platform for biological drugs (peptides and proteins) based on the use of elastin-like polypeptides (ELP's). PhaseBio's engineered proteins and peptides have improved manufacturing, pharmacokinetic, and pharmacodynamic properties. The company's lead programs in phenylketonuria (PKU), diabetes, and respiratory diseases are entering clinical trials.
SpineAlign is a medical device company that has developed an implantable device to treat vertebral compression fractures. The company has received a CE Mark and has completed a 50 patient study in Europe. The company's device shows the ability to restore height and reduce pain. The U.S. trial and 501(k) process is commencing.
Viamet is discovering new drugs that inhibit metalloenzymes. Metalloenzymes are targeted by 10% of all currently approved drugs. Using a proprietary drug discovery platform, Viamet can design drugs with improved efficacy and safety properties. The company's lead programs in fungal disease and hormone resistant prostate cancer are at candidate selection stage.
Hatteras Venture Partners II, LP (HVP II) is a $35 million venture capital fund closed in May of 2004. HVP II involved two relationships between Hatteras and HBM Partners of Switzerland, and related entities. In the first relationship, HVP II is a $34.5 million limited partner in HBM BioCapital (USD), LP, a Cayman Island limited partnership that was invested alongside HBM BioCapital (EUR), LP from 2004 to the present (the combined fund (HBM BioCapital) has approximately $150 million under management). In the second relationship, Hatteras BioCapital, LLC, the General Partner for HVP II, is an investment advisor and part of the investment team for HBM BioCapital. Through this relationship, Hatteras and HBM worked collaboratively to develop the following portfolio of 15 clinical stage companies in the United States and Europe:
Hatteras Venture Partners I (HVP I) is a $3 million venture capital fund focused on pre-seed and seed investments in human medicine and information technology. HVP I was launched in late 2000.
Entegrion, Inc.
Based upon technology from UNC and East Carolina University that was funded by over a decade of Department of Navy funding, Entegrion is developing hemostatic technologies for wound management, tissue repair, and control of hemorrhage. The company's lead product (Stasilon-FR, formerly AlphaBandage) is FDA approved for use as an external hemostatic bandage.
Noverant provides web-based Learning Management Systems for Training, Compliance, and Auditing for small and medium-sized businesses. Our comprehensive, user-friendly software and services provide low-cost and company-wide solutions resulting in 100% of a company's training requirements - conforming internally and externally with any and all Regulatory Agencies.
Respirics is a respiratory drug company focused on development and delivery of powdered formulations of important respiratory medications. The company's Accu-Breathe delivery device is the first of its kind to enable the dispensing of powdered drug as the patient inhales, improving patient compliance and therapy. Respiric's lead program is Accu-30 Albuterol, the first powdered form of albuterol in clinical development in the United States.
PhaseBio is a biopharmaceutical company applying a flexible new platform for biological drugs (peptides and proteins) based on the use of elastin-like polypeptides (ELP's). PhaseBio's engineered proteins and peptides have improved manufacturing, pharmacokinetic, and pharmacodynamic properties. The company's lead programs in phenylketonuria (PKU), diabetes, and respiratory diseases are entering clinical trials.
Synthematix (now Symyx Technologies, Inc. - SMMX) is focused on developing and deploying software solutions for discovery and medicinal chemists. In April 2005, Synthematix was acquired by Symyx Technologies for $13MM cash (giving HVP a return multiple of 5.5X).
|
